Zinc Transporter 8 (ZnT8) Autoantibody
Enzyme linked immunosorbent assay (ELISA) for the quantitative determination of autoantibodies to the zinc transporter 8 (ZnT8) in serum
Procedure
25 microlitre calibrators, controls and samples into wells,
18 hrs. incubation, 3 x wash
add ZnT8 biotin, 1h incubation
3 x wash, add SAPOD, 20 min incubation
3 x wash, add substrate. 20 min incubation
stop reaction + read
Characteristics
Reliable and convenient method to measure specific ZnT8 antibodies which are major component of ICA in type 1 DM and wihich are useful for diagnosis and prediction of type 1 DM. The non-isotopic assy is suitable in routine clinical laboratories in automated or manual formats.
The ZnT8 autoantibody (ZnT8 Ab) ELISA kit is intended for use for the quantitative determination of ZnT8 autoantibodies in human serum. Autoantibodies to pancreatic beta cell antigens are important serological markers of type 1 diabetes mellitus (type 1 DM). The antigens recognised by these antibodies include insulin, glutamic acid decarboxylase (GAD65 kDa isoform), the islet cell antigen IA-2 or ICA-512 and zinc transporter 8 (ZnT8). ZnT8 autoantibodies are directed principally to the C terminal domain of ZnT8 (residues 268 – 369). Human population gene polymorphism at the codon for the 325th amino acid results in the expression of three protein variants: Arginine (R) 325, Tryptophan (W) 325 and very rarely Glutamine (Q) 325. ZnT8 autoantibodies may be specific to the R 325 or W 325 variant, or may be residue 325 non-specific. Sera that react with the Q allele only are extremely rare. ZnT8 autoantibody ELISA is capable of detecting, and quantifying, autoantibodies specific to R 325 or to W 325, or to residue 325 non-specific variants.
In ZnT8 Ab ELISA, ZnT8 autoantibodies in test patients’ sera, calibrators and controls are allowed to interact with ZnT8 coated onto ELISA plate wells. After a 16 – 20 hour incubation, the samples are discarded leaving ZnT8 autoantibodies bound to the ZnT8 coated wells. ZnT8 Biotin is added in a 2 nd incubation step where, through the ability of ZnT8 autoantibodies in the samples to act bivalently (or polyvalently), a bridge is formed between ZnT8 bound to the wells and ZnT8 Biotin. Unbound ZnT8 Biotin is then removed in a wash step and the amount of bound ZnT8 Biotin determined (in a 3 rd incubation step) by addition of Streptavidin Peroxidase (SA-POD), which binds specifically to Biotin. Excess, unbound SA-POD is then washed away and addition of 3,3’,5,5’ – tetramethylbenzidine (TMB) results in formation of a blue colour. This reaction is stopped by addition of stop solution causing the well contents to turn yellow. The absorbance of the yellow reaction mixture at 405 nm and 450 nm is then read using an ELISA plate reader. A higher absorbance indicates the presence of ZnT8 autoantibody in the test sample. Reading at 405 nm allows quantitation of high absorbances. Low values (less than 50 units per ml) should be read off the 450 nm calibration curve. The measuring range is 10 – 2000 u/ml.
The following patents apply: European patents 1563071 B1 and 2118309 B1, US patents 7,851,164 B2 and 9,023,984 B2, Chinese patent CN1738900B, Japanese patents 4498144 and 5694668.
- J. M. Wenzlau et al “The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in
human type I diabetes.” PNAS 2007 104:17040-17045 - P. Achenbach et al “Autoantibodies to zinc transporter 8 and SLc30A8 genotype stratify type
1 diabetes risk.” Diabetologia 2009 52:1881-1888 - J. M. Wenzlau et al “Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects.” J Clin Endocrinol Metab 2010 95:4712 – 4719
- L. Petruzelkova et al “The dynamic changes of zinc transporter 8 autoantibodies in Czech children for the onset of type 1 diabetes mellitus.” Diabet Med 2014 31:165 – 71
- G. Dunseath et al “Bridging-type enzyme-linked immunoassay for zinc transporter 8 autoantibody measurements in adult patients with diabetes mellitus.” Clin. Chim. Acta. 2015 447:90 – 95